Maridebart Cafraglutide vs Retatrutide: Two Approaches to Triple-Pathway Weight Loss Research
Maridebart cafraglutide antagonizes GIP; retatrutide agonizes it. Both hit ~20% Phase 2 weight loss — compare receptor mechanisms, dosing, and Phase 3 status.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Maridebart cafraglutide and retatrutide represent two competing strategies for extending weight-loss efficacy beyond single-pathway GLP-1 agonism, and researchers comparing incretin-class pipeline compounds increasingly ask how a GIP-antagonist antibody conjugate stacks up against a GIP-agonist small peptide triagonist. Both are Phase 3 investigational compounds targeting overlapping metabolic pathways through mechanistically opposite approaches to the GIP receptor, and neither has received FDA approval.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Maridebart cafraglutide (MariTide) combines GLP-1 receptor agonism with GIP receptor antagonism in a once-monthly peptide-antibody conjugate, while retatrutide is a once-weekly small peptide that agonizes GLP-1, GIP, and glucagon receptors simultaneously — both are Phase 3 investigational compounds with no FDA approval, differing primarily in dosing interval, molecular format, and their opposite approach to the GIP receptor.
TL;DR:
- Maridebart cafraglutide antagonizes GIP while agonizing GLP-1; retatrutide agonizes GIP, GLP-1, and glucagon simultaneously — a mechanistic contradiction that reflects an unresolved scientific debate about GIP's optimal role in weight regulation.
- Phase 2 data (MARITIME-1, NEJM 2025) showed up to ~20% body weight reduction at 52 weeks for maridebart cafraglutide in participants without diabetes.
- Retatrutide's PMID 41997446 mechanistic dataset demonstrates that GIP and glucagon receptor co-agonism can correct obesity even without functional GLP-1 receptor activity, based on rodent knockout models.
- Maridebart cafraglutide is dosed monthly or less often via its antibody-conjugate backbone; retatrutide, as a small peptide, follows a weekly subcutaneous schedule.
- Neither compound holds FDA approval; both remain Phase 3 investigational biologics not eligible for 503A pharmacy compounding.
Maridebart cafraglutide: mechanism and evidence base
Maridebart cafraglutide (development code AMG 133, informally called MariTide) is a long-acting peptide-antibody conjugate developed by Amgen. Its defining structural feature is the fusion of a GLP-1 receptor-agonist peptide to an antibody fragment, which extends circulating half-life to roughly three weeks and enables once-monthly or less-frequent subcutaneous dosing — an unusually long interval within the incretin research field. Full compound data, including chemistry and trial cross-references, is maintained on the maridebart cafraglutide library profile.
Mechanistically, maridebart cafraglutide pairs GLP-1 receptor agonism, which suppresses appetite and slows gastric emptying, with GIP receptor antagonism — a deliberately opposite approach to GIP compared with GIP-agonist molecules such as tirzepatide. In the Phase 2 MARITIME-1 trial (New England Journal of Medicine, June 2025; PMID 40549887; NCT05669599), 592 adults with obesity or overweight were randomized across a dose-ranging design. At 52 weeks, participants without diabetes lost up to approximately 20% of body weight versus 2.6% with placebo, and weight loss had not plateaued. Participants with type 2 diabetes lost up to approximately 17% of body weight versus 1.4% with placebo, with HbA1c reductions of up to 2.2 percentage points.
Amgen has since advanced maridebart cafraglutide into a six-trial Phase 3 program, MARITIME, spanning obesity and overweight without diabetes (NCT06858839), obesity and overweight with type 2 diabetes (NCT06858878), cardiovascular outcomes (NCT07037433), obstructive sleep apnea (NCT07225686), elevated liver fat (NCT07441252), and a Japan-specific obesity study (NCT06987695). The program is expected to run through January 2027, and current trial status can be tracked on the site's clinical trial tracker.
Retatrutide: mechanism and evidence base
Retatrutide is a balanced, unimolecular small peptide designed as a triagonist across three metabolic receptors: the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Unlike maridebart cafraglutide's antibody-conjugate architecture, retatrutide is a conventional peptide therapeutic administered by weekly subcutaneous injection. Full profile data is available on the retatrutide library page.
A mechanistic study underpinning retatrutide's receptor pharmacology (PMID 41997446) used diet-induced obese and GLP-1 receptor knockout mouse models to test whether obesity correction requires functional GLP-1 receptor activity. The research found that retatrutide, as a balanced GLP-1R:GIPR:GCGR triagonist, normalized body weight in obese mice lacking a functional GLP-1 receptor, indicating that GIPR and GCGR co-agonism alone can drive substantial weight loss. A related fatty-acylated GIPR:GCGR co-agonist (BWB3054) matched retatrutide's weight-lowering effect in obese mice despite more than 100-fold reduced potency at the GLP-1 receptor, reinforcing that the glucagon and GIP pathways carry independent therapeutic weight relative to GLP-1 agonism.
This mechanistic evidence base sits alongside retatrutide's separately reported Phase 2 human trial data (Jastreboff et al., New England Journal of Medicine, 2023), which recorded mean body weight reductions of up to 24.2% over 48 weeks in adults with obesity — among the largest reductions reported for any incretin-pathway compound to date. Retatrutide's ongoing Phase 3 program is evaluating longer-term safety and efficacy across multiple obesity and metabolic-disease populations; comparative mechanism data against the market-leading dual agonist tirzepatide is available on the site's dedicated comparison article.
The distinguishing feature of retatrutide's research profile is that it does not merely add a third receptor target for incremental effect — the knockout-mouse data specifically isolates which receptor combinations are necessary versus dispensable for weight correction. This matters for basic-science interpretation: if GIPR and GCGR agonism alone (in a GLP-1R-null background) can normalize body weight, then the therapeutic ceiling of incretin-pathway pharmacology may not be capped by GLP-1 receptor saturation, a finding with implications for how future multi-agonist molecules are designed.
Why the field is testing GIP agonism and antagonism in parallel
The apparent contradiction between maridebart cafraglutide's GIP antagonism and retatrutide's GIP agonism is not a case of one program being scientifically mistaken. Preclinical rodent literature has reported weight-loss benefit from both directions of GIP receptor modulation, depending on the co-agonist context, dosing regimen, and whether GIP signaling is chronic versus intermittent. Some earlier basic-science work suggested that constant GIP receptor antagonism could reduce adipose tissue accumulation and improve insulin sensitivity, motivating the antagonist design chosen for maridebart cafraglutide. Retatrutide's design instead builds on evidence that balanced agonism across all three receptors — GLP-1R, GIPR, and GCGR simultaneously — produces synergistic rather than competing effects on energy expenditure and appetite suppression. Because both approaches have now reached Phase 3 human testing with substantial reported weight loss, head-to-head comparative research (rather than mechanism-only rodent studies) will likely be needed to resolve which GIP-pathway strategy, if either, proves superior across broader populations.
Side-by-side comparison
| Attribute | Maridebart cafraglutide | Retatrutide |
|---|---|---|
| Molecular format | Peptide-antibody conjugate | Small unimolecular peptide |
| Receptor targets | GLP-1R agonist, GIPR antagonist | GLP-1R, GIPR, GCGR triagonist |
| GIP receptor approach | Antagonism | Agonism |
| Dosing interval (studied) | Monthly or less frequent | Weekly |
| Route of administration | Subcutaneous injection | Subcutaneous injection |
| Approximate half-life | ~3 weeks | Days (weekly dosing regimen) |
| Phase 2 weight loss (no diabetes) | ~20% at 52 weeks | Up to ~24.2% at 48 weeks (human trial) |
| Developer | Amgen | Eli Lilly |
| Current development stage | Phase 3 (MARITIME program) | Phase 3 |
| FDA approval status | Investigational | Investigational |
| 503A compounding eligibility | Not eligible (biologic conjugate) | Not eligible (investigational peptide) |
Differential research applications
The two compounds represent a genuine, unresolved scientific question about GIP receptor pharmacology in weight regulation: should GIP be agonized or antagonized to potentiate GLP-1-driven weight loss? Retatrutide's rodent knockout data (PMID 41997446) demonstrates that GIPR and GCGR agonism can substitute for GLP-1R activity entirely, supporting a receptor-agonism strategy. Maridebart cafraglutide's clinical program instead tests GIP antagonism layered onto GLP-1 agonism, following earlier basic-science observations that chronic GIP receptor blockade may improve insulin sensitivity in some models.
Researchers designing comparative or translational studies may select retatrutide when the goal is characterizing simultaneous multi-receptor agonism and its downstream signaling convergence, since all three targets are activated by a single peptide with well-characterized receptor binding kinetics. Maridebart cafraglutide is more often selected when the research question concerns antibody-conjugate pharmacokinetics, extended half-life engineering, or GIP antagonism specifically as a mechanism distinct from agonist-based approaches. Dosing-interval modeling and cross-compound trial status comparisons can be cross-referenced using the trial tracker tool, which aggregates current Phase 3 recruitment status across incretin-pathway compounds.
Regulatory and compounding status
Neither compound has received FDA approval as of this writing. Maridebart cafraglutide remains investigational, with its Phase 3 MARITIME program running across six global trials through an expected January 2027 completion window. As a peptide-antibody conjugate biologic, it is not eligible for 503A pharmacy compounding. Retatrutide is likewise investigational and Phase 3-stage; as a peptide still under FDA review pathways, it is not eligible for 503A bulk drug substance compounding at this time. Researchers should note that both compounds' regulatory classifications differ structurally from the seven peptides recently reviewed under the FDA's Pharmacy Compounding Advisory Committee 503A nomination process, since neither maridebart cafraglutide nor retatrutide has been nominated for that bulk drug substance list — both are instead proceeding through the standard investigational new drug and eventual biologics/new drug application pathway.
Cited studies
- PMID 40549887 — "Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial." (New England Journal of Medicine, 2025). https://doi.org/10.1056/NEJMoa2504214
- PMID 41997446 — "GIPR:GCGR co-agonism restores normal weight in obese rodents." (2026). https://doi.org/10.1056/NEJMoa2301972
Frequently asked questions
Q: Is maridebart cafraglutide the same as MariTide?
A: Yes. MariTide is the informal working name used for maridebart cafraglutide (development code AMG 133) throughout Amgen's published trial materials and much of the research literature discussing the compound.
Q: Why does retatrutide agonize GIP while maridebart cafraglutide antagonizes it?
A: The two programs reflect competing hypotheses about GIP's role in weight regulation. Retatrutide's underlying research (PMID 41997446) found that GIP receptor agonism combined with glucagon receptor agonism can drive weight loss independent of GLP-1 activity, while maridebart cafraglutide's development pursued GIP antagonism as a separate mechanism for improving metabolic outcomes alongside GLP-1 agonism.
Q: What is the dosing interval difference between the two compounds?
A: Maridebart cafraglutide's antibody-conjugate structure extends its half-life to approximately three weeks, supporting monthly or less-frequent subcutaneous dosing in trials. Retatrutide, as a conventional peptide, follows a weekly subcutaneous dosing schedule in its published trial protocols.
Q: Has either compound been FDA approved?
A: No. Both maridebart cafraglutide and retatrutide are investigational compounds in Phase 3 clinical development as of 2026, with no FDA approval for any indication.
Q: Can either compound be obtained through 503A compounding pharmacies?
A: No. Both are investigational biologics or peptides still in Phase 3 trials and have not been nominated to or placed on the FDA's 503A bulk drug substance list, making them ineligible for pharmacy compounding under current regulations.
See also:
- Retatrutide vs Tirzepatide: Triple vs Dual Agonist Mechanism Comparison — compares retatrutide's triagonist design against the currently marketed dual-agonist tirzepatide.
- Retatrutide TRIUMPH-1 Phase 3 Results — detailed breakdown of retatrutide's Phase 3 trial data and endpoints.
- Emerging GLP-1 Incretin Pipeline: 2026 Overview — broader context on investigational incretin-pathway compounds including maridebart cafraglutide.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.